Gilead reports 23% placebo-adjusted remission with emvistegrast
Gilead Sciences reported that its oral drug emvistegrast produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis in a 12-week Phase 2 study. The improvement was statistically significant and exceeded Wall…
